$2.030
-0.039 (-1.93%)收盤時
- 最高
- 2.150
- 開盤
- 2.070
- 成交量加權均價
- 2.06
- 成交量
- 28.49K
- 市值
- —
- 最低
- 2.010
- 成交金額
- 58.78K
- 企業價值/稅息折舊攤銷前利潤(TTM)
- -1.66
QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology.
AI 分析 of QT Imaging Holdings Inc (QTI)
買進QT Imaging Holdings Inc (QTI) presents a compelling buy opportunity at the current price of $2.03, especially considering its recent 103% revenue growth in Q2 2026, which indicates strong market demand. The RSI is at a low 19.071, suggesting the stock is oversold and may rebound. However, the main risk is the significant net income loss of $11.07 million in Q2 2026, which investors should monitor closely.
估值指標
事件時間軸
資訊
1.011-05NewsfilterQT Imaging to Participate in MedTech Forum
7.510-07NewsfilterQT Imaging Partners with Premier for National Agreement
8.510-01NewsfilterQT Imaging's CPT Code 1079T Effective Early
8.509-29NewsfilterQT Imaging to Ring Nasdaq Closing Bell on October 2, 2026 for Breast Cancer Awareness
8.509-22NewsfilterQT Imaging Honored for FDA-Cleared Breast Imaging Technology
QTI 常見問題 —— 由 Alphio AI 解答
QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).
QT Imaging Holdings Inc (QTI) presents a compelling buy opportunity at the current price of $2.03, especially considering its recent 103% revenue growth in Q2 2026, which indicates strong market demand. The RSI is at a low 19.071, suggesting the stock is oversold and may rebound. However, the main risk is the significant net income loss of $11.07 million in Q2 2026, which investors should monitor closely.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。